Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab + Pola-R-CHP in high-risk DLBCL guided by interim PET and ctDNA
ChiCTR2600118538Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Feb 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Peking Union Medical College Hospital. Primary endpoint: Complete remission rate (CRR). Planned start Feb 2026; status: not yet recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2600118538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118538.